Phospholipid nanoform for oral application (sachet) and method for preparing it (versions). RU patent 2463057.

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, pharmacology and concerns an oral granulated dosage form in sachets containing phospholipids in the form of particles of small (20-30 nm) diameter, glycyrrhizic acid and its salt (including sodium glycerrhizinate), as well as carbohydrate (including maltose) and excipients (granulation, anti-clotting and powder), as well as to a method for preparing it by mixing fat and water phases of herbal phospholipids and acceptable carbohydrate to prepare an emulsion, cooling to 50°C and passing through a microfluidiser for 4-5 cycles under pressure 2000 atm.

EFFECT: preparation shows high activity.

6 cl, 1 tbl, 5 ex

IPC classes for russian patent Phospholipid nanoform for oral application (sachet) and method for preparing it (versions). RU patent 2463057. (RU 2463057):

B82B1 - Nano-structures formed by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units

A61P1/16 - for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

A61K9/127 -

A61K31/685 -

Another patents in same IPC classes:

Composition for drug substance integration into lipid matrix, drug composition with phospholipid fatty acid system and method for preparing them / 2463056
Invention refers to medicine and pharmaceutics, and concerns a storage-stable composition in the form of nanoparticles of size 10-20 nm containing a fatty acid salt, phosphatidyl choline and maltose for the integration of biologically active substances, particularly, drugs, as well as drug compositions containing the fatty acid salt, phosphatidyl choline, maltose and a drug substance, and a method for preparing them.

Hybrid nanocomposite materials / 2462793
Invention is aimed at producing hybrid nanocomposite material which contains conducting inorganic elongated crystals with an electrically conducting organic compound of given formula grafted on at least part of its surface, said compound forming a self-organising layer. The invention also discloses thin films, solar batteries and switching devices containing said hybrid nanocomposite material.

Optical nanogenerator / 2462740
Device has a pair of telescopic nanotubes, a constant optical signal source, two output optical nano-waveguides, two constant optical signal sources, two power supplies, two groups of electric contacts and an optical nano-waveguide Y-splitter.

Method to form nanosized pattern on substrate (versions) and structure with pattern comprising nanosized self-assembled self-built structures / 2462412
Invention relates to self-assembling sublithographic nanosized structures in an orderly periodical grid and to methods of their manufacturing. The concept of manufacturing is as follows: the method to form a nanosized pattern on a substrate includes formation of the first stenciled layer, covering the specified area on the substrate, arrangement of a system of first holes in it, each of which has a shape of a rectangular hexagon and which are arranged in cells of the first hexagonal grid, formation of the first nanosized self-assembled self-built structures in the first holes, formation of the second stenciled layer covering the specified section, arrangement of a system of second holes in the second stenciled layer, each of which has a shape of regular hexagon and which are arranged in cells of the second hexagonal grid, formation of the second nanosized self-assembled self-built structures in the second holes, formation of the third stenciled layer covering the specified section, arrangement of a system of third holes in the third stenciled layer, every of which has a shape of regular hexagon, and which are arranged in cells of the third hexagonal grid, and formation of the third nanosize self-assembled self-built structures in third holes.

Method of producing ag/sio<sub>2</sub> catalyst for heterogeneous catalysis of molecular hydrogen in protium-deuterium isotopic exchange reactions and ortho-para conversion of protium

Method of producing ag/sio₂ catalyst for heterogeneous catalysis of molecular hydrogen in protium-deuterium isotopic exchange reactions and ortho-para conversion of protium / 2461413
Invention relates to heterogeneous catalysis, particularly a method of producing a catalyst for protium-deuterium isotopic exchange and ortho-para conversion of protium. Disclosed is a method of producing a Ag/SiO2 catalyst for heterogeneous catalysis of molecular hydrogen in form of a protium-deuterium isotopic exchange reaction or ortho-para conversion of protium. The method involves obtaining silver nanoparticles by reducing silver ions from a reverse micellar solution of silver and depositing the obtained silver nanoparticles onto a SiO2 support which is immersed into the solution. The silver ions are reduced from a reverse micellar solution of silver which is prepared by adding 0.03-2.0 M AgNO3 aqueous solution and 0.000075-0.0002 M quercetin solution as a reducing agent to 0.02-0.5 M solution of sodium bis(2-ethylhexyl)sulphosuccinate in a nonpolar solvent - isooctane, followed by treatment of the obtained solution with ultrasound until formation of a reverse micellar dispersion.

Method of producing ag/sio₂ catalyst for heterogeneous catalysis of molecular hydrogen in protium-deuterium isotopic exchange reactions and ortho-para conversion of protium / 2461412
Invention relates to heterogeneous catalysis, particularly a method of producing a catalyst for protium-deuterium isotopic exchange and ortho-para conversion of protium. Disclosed is a method of producing a Ag/SiO2 catalyst for heterogeneous catalysis of molecular hydrogen in form of a protium-deuterium isotopic exchange reaction or ortho-para conversion of protium. The method involves obtaining silver nanoparticles via radiation-chemical reduction of silver ions from a reverse micellar solution of silver and depositing the obtained silver nanoparticles onto a SiO2 support which is immersed into the solution, wherein silver ions are reduced from a reverse micellar solution of silver which is prepared by adding 0.003-2.0 M AgNO3 aqueous solution to 0.02-0.5 M solution of sodium bis(2-ethylhexyl)sulphosuccinate in a nonpolar solvent - isooctane and treating the obtained solution with ultrasound until formation of a reverse micellar dispersion, followed by deaeration thereof to a suspension which is exposed to γ-radiation of 60Co with a dose of 5-30 kGy.

Method of determining polyhexamethylene guanidine hydrochloride / 2460998
Method involves reaction of reactants followed by analysis of the obtained products. According to the invention, the reactant used is a colloidal solution of gold nanoparticles in water. After reaction, the obtained product (gold nanoparticles and aggregates thereof) are concentrated on foamed polyurethane and the concentrate is analysed.

Method for preparing composition containing colloidal nanosilver or nanogold (versions) / 2460797
Method for preparing a composition containing colloidal nanosilver or nanogold involves incubation of probiotic bacteria specified in Lactobacillus fermentum species with an aqueous solution containing at least 4 mM of silver nitrate or auric chloride. The composition containing colloidal nanosilver is prepared by contact of said bacteria at 5-45°C and the aqueous solution containing mixed silver nitrate, ammonium and/or ammonia salt, as well as alkali metal hydroxide. The composition containing colloidal nanogold is prepared by contact of said bacteria at 5-45°C and the aqueous solution containing mixed auric chloride and alkali metal hydroxide.

Universal thick-layer anticorrosion paint system / 2460748
Universal thick-layer anticorrosion paint system includes an aqueous aryl-containing dispersion with a crosslinking agent, target additives, an instant corrosion inhibitor, a water-soluble organic corrosion inhibitor, an anticorrosion pigment and other pigments, nanodispersed silicon dioxide, plate-like and active filler and water. Corrosion inhibitors and the anticorrosion pigment are capable of forming nanosized protective layers on a metal surface under a paint film. The nanodispersed silicon oxide provides thick-layered application of the paint coat. In order to seal the paint coat structure and increase enhance its water-repellent properties, nanodispersed fluoroplastic is additionally used in the paint system.

Rubber compositions / 2460744
Composition contains filler as well as (i) at least one rubber which contains an unsaturated olefin fragment and (ii) less than 2 parts/100 parts rubber and preferably more than 0.1 parts/100 parts particles of functionalised nanosized zinc oxide. Said particles are particles of nanosized zinc oxide with a coating agent. The composition is obtained by mixing said components, preferably with addition of a primary vulcanisation accelerator in total amount of 0.5-4 parts/100 parts rubber. The composition is used as or in a component of tyres, belts and hoses.

Agent showing hepatoprotective action, and method for preparing it / 2462259
Invention refers to pharmaceutical industry, specifically to an agent showing hepatoprotective action. The agent showing hepatoprotective action of a herbal polyphenol extract of Amur maackia heartwood (Maxar) which represents an aqueous solution of Maxar in the molecular-capsulated form in the form of a water-soluble associated with a surfactant having a specific hydrophilic-lipophilic balance. A method for preparing the agent showing hepatoprotective action by Maxar homogenisation in the melt surfactant under certain conditions to produce the molecular-capsulated form of the end product.

Method of treating patients with chronic liver diseases in stage of latency and degree i manifested stage of hepatic encephalopathy / 2462251
Invention refers to medicine and aims at treating the patients with chronic liver diseases (CLD) in the stage of latency and degree I manifested stage of hepatic encephalopathy. The preparation Essentiale forte N is used. It is combined with prescribing the preparation Mucofalk. The course is 28-30 days.

Method of treating chronic viral hepatitis c / 2459629
Invention refers to medicine, namely hepatology and may be applicable in treating chronic viral hepatitis C. That is ensured by introducing short-lived interferon-alpha (IFN) and the nucleoside analogue Ribamidil in the patient with an initial average week dosage specified in the range of 10.5 to 21.0 mil. IU depending on the level of native patient's interferon-alpha. Interferon-alpha is introduced with at least twice gradually increase of the average week dose to 21.0 to 84 mil. IU. Over the whole period of introducing IFN, the patient is prescribed with additional antiviral preparations - an interferon inducer, as well as an amantadin preparation or a glycyrrhizic acid preparation. It is combined with a support therapy involving the introduction of T-cell immunity stimulators and preparations for correction of side effects. The presence of blood viral ribonucleic acid is occasionally controlled and the introduction of Ribamidil is started in a daily dose of 800-1200 mg from the third month from the beginning of treatment if observing the presence of ribonucleic acid or from the tenth month if observing the absence. The treatment is continued until at least a 12-month aviremia period is achieved.

Method of prevention and treatment of liver disease with application of receptor a<sub>2b</sub> antagonists

Method of prevention and treatment of liver disease with application of receptor a_2b antagonists / 2457842
Group of inventions relates to field of medicine. Method of treatment and prevention of liver fibrosis includes peroral introduction to mammal of therapeutically efficient amount of antagonist of adenosine receptor A2B - 3-ethyl-1-propyl-8-(1-{[3-(trifluormethyl)phenyl]methyl}pyrazol-4-yl)-1,3,7-trihydropurine-2,6-dione. Method of reducing hepatotoxic side effects of chemical therapy or radiotherapy includes peroral introduction to mammal who underwent such treatment of therapeutically efficient amount of antagonist of adenosine receptor A2B - 3-ethyl-1-propyl-8-(1-{[3-(trifluormethyl)phenyl]methyl}pyrazol-4-yl) -1,3,7-trihydropurine-2,6-dione.

Granule and method for making thereof / 2456980
Invention refers to pharmaceutics. A pharmaceutical granule is spherical or spheroidal and has volume density 0.6-1.3 g/ml and disintegration 0.5-5 minutes. Active pharmaceutical ingredients are preparations of Traditional Chinese Medicine, herbal preparations or their extracts with a nucleus made of an extract of Traditional Chinese Medicine or herbal preparations, and a pharmaceutically acceptable carrier. The content of the pharmaceutically acceptable carrier with respect to total granule weight makes 10-60 wt %. The granule diameter can be equal to 700-1500 mcm. The granule nucleus diameter can be equal to 200-750 mcm. The granule can be also coated with a layer of 2-5 wt % with respect of total granule weight. A method for making the granules consists in introducing initial granules into a layer of a fluidised material as an excipient; the active pharmaceutical ingredients are prepared in the form of a suspension or a solution of the viscosity controlled within 6.0-9.8 MPa·s with using a viscosity-control agent; then they are sprayed over a surface of the initial granule for making a finished granule.

Method for preventing and treating hepatic consequences of ischemia / 2456678
Liver is resected in an animal experimentally. A pharmacological protection is presented by Mexicor and Serotonine Adipinate. On the operation day, 5% Mexicor is used in the form of intravenous slow stream introductions twice - 35 minutes before the operation in a dose of 5 mg/kg of weight and 11 hours after the first introduction in a dose of 7 mg/kg of weight. Serotonine Adipinate dissolved in 5 ml of isotonic solution NaCl is used in the form of intravenous slow stream introductions three times - 1 hour before the operation in a dose of 0.15 mg/kg of weight, 2 hours after the first introduction in a dose of 0.2 mg/kg of weight, 10 hours after the first introduction in a dose of 0.1 mg/kg of weight. During the postoperative period, Mexicor and Serotonine Adipinate are introduced for 8 days. Mexicor is introduced three times a day at 9 o'clock in a dose of 2.5 mg/kg of weight, at 15 o'clock in a dose of 1.5 mg/kg of weight, at 21 o'clock in a dose of 6 mg/kg of weight. Serotonine Adipinate is introduced twice a day - at 8 o'clock in a dose of 0.15 mg/kg of weight, at 17 o'clock in a dose of 0.1 mg/kg of weight.

Benzimidazole derivatives, based pharmaceutical composition and methods of using them / 2456276
Present invention refers to new benzimidazole derivatives of general formula (I) or to its pharmacologically acceptable salts wherein R1 represents a C6-aryl group which can be substituted by 1-3 groups optionally specified in a group of substitutes (a), or a heterocyclic group which represents pyridyl, dihydrobenzofuranyl, 1,3-benzodioxolyl, tetrahydropyranyl, tetrahydrofuranyl which can be substituted by 1-3 groups optionally specified in a group of substitutes (a), R2 represents a C1-C6 alkyl group, R3 represents a C6-aryl group which can be substituted by 1-2 groups optionally specified in a group of substitutes (a), Q represents a group represented by formula =CH-, or a nitrogen atom and a group of substitutes (a) represents a group consisting of a halogen atom, a C1-C6 alkyl group, a C1-C6 halogenated alkyl group, a carboxyl group, a C2-C7 alkylcarbonyl group, a C2-C7 alkoxycarbonyl group, a C1-C6 alkoxy group, a C1-C6 halogenated alkoxy group, an amino group, a 4-morpholinyl group and a di-C1-C6 alkyl)amino group. Also, the invention refers to a pharmaceutical composition based on a compound of formula (I), to a PPARγ activator/modulator based on the compound of formula (I), to using the compound of formula (I), to a method of reducing blood glucose, to a method of activating PPARγ, a method of treating and/or preventing said pathological conditions.

Method of preventing liver injury in formation of syndrome of combined dystrophic-degenerative changes of mesenchimal derivatives in case of local chronic inflammatory process and means for its realisation / 2455988
Claimed is means for prevention (prophylaxis) of liver injury in formation of syndrome of combined dystrophic-degenerative changes of mesenchimal derivatives in case of local chronic inflammatory process, located outside the liver (CDDCMD in case of LCIP located outside the liver), which represents hormone of pineal gland - melatonin and corresponding method of prevention (prophylaxis) of liver injury in formation of CDDCMD in case of LCIP.

Method of treating dyskinesia of gallbladder at background of chronic psycho-emotional stress / 2455970
Invention relates to medicine, namely to physiotherapy, gastroenterology. Method includes introduction of diet No5, internal intake of mineral water with the following carrying out transverse galvanisation of epigastrium area, general coniferous baths and impact with physical factor. As physical factor used is electromagnetic radiation of extremely high frequency (EHF). Impact is performed by broad-band noise emitter with frequency 40-63 GHz. Impact is performed on 3 and 4 projection zones in area of the right hypochondrium and on the area of sternum. Impact is performed daily, 10 minutes on each zone. Course includes 10-12 procedures.

Method for stimulating liver regeneration in fibrotic changes in experiment / 2455701
Under the conditions of modelling cirrhosis in experiment, the preparation EMBRYOBLASTE is introduced in liver tissue by means of an injector needle at the depth up to 0.1 cm. The preparation is introduced along a front surface of the liver, 2 injections in each lobe of the liver to form a papula. The volume of one injection makes 0.3 ml.